Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

30%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 4

2(25.0%)

Early Phase 1

1(12.5%)

Phase 3

1(12.5%)

8Total

Phase 2(4)

Phase 4(2)

Early Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07475546Phase 3Active Not Recruiting

Combination Gerotherapeutic Interventions for Healthspan Improvement

Role: lead

NCT07092618Phase 2Recruiting

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

Role: lead

NCT07092605Early Phase 1Enrolling By Invitation

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Role: lead

NCT06550271Completed

The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals

Role: lead

NCT05307627Withdrawn

The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging

Role: lead

NCT06301529Phase 4Completed

The Efficacy and Tolerability of Canagliflozin in Healthy Individual

Role: lead

NCT04488601Phase 2Completed

Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study

Role: lead

NCT05542849Phase 4Completed

The Efficacy and Tolerability of Acarbose in Healthy Individuals

Role: lead

NCT04604704Phase 2Completed

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

Role: lead

NCT04604678Phase 2Withdrawn

Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19

Role: lead

All 10 trials loaded